Shrooms Vs. LSD: Are They the Same?

During the general elections held in November 2020, Oregon voters made history by passing Measure 110 and Measure 109. The former decriminalizes the possession of small amounts of all illicit substances while the latter allows adult use of psilocybin mushrooms in a therapeutic setting.

Psychedelics are made up of various substances including LSD, commonly known as acid, and “magic” mushrooms, or psilocybin mushrooms. While there are some similarities between both LSD and mushrooms, both may elicit experiences that differ in individuals.

Psilocybin is a psychedelic component found in the mushroom species Psilocybe cubensis. On the other hand, LSD’s origin was less natural, coming from Albert Hoffman’s lab. Hoffman was a Swiss chemist who synthesized the psychedelic substance from a mold known as ergot.

The following include a few effects of both LSD and psilocybin mushrooms;

• Dilated pupils
• Excitement
• Rapid heart rate
• Distorted perception of time
• Sensation that solid objects are melting
• Altered sense of smell, touch and taste
• Occasional tremors, sweat and numbness
• Spiritual awakenings
• Elevated blood pressure
• Paranoid delusions
• An increased sense of connection
• Sensation that stationary objects are moving
• Auditory and visual hallucinations

However, while both psychedelic substances may cause similar effects, they produce separate experiences owing to the duration of the effects and difference in onset time. Both psychedelics take roughly an hour to begin having an effect when taken on an empty stomach. If taken after a meal, the time frame before experiencing any impact may be longer. Experienced psychedelic-assisted therapists can help determine the ideal time for ingestion based on assessment of needs.

Additionally, the substances are ingested in different ways, with LSD either being applied to small paper tabs that dissolve in an individual’s mouth or consumed from a dropper. Conversely, magic mushrooms are dried then either brewed into a tea or eaten under the watchful eye of an experienced and licensed medical professional.

With regard to dosage, LSD should be taken in small quantities. In addition, it should be noted that it is easy to consume more LSD than a person can handle, which is why these substances should always be taken under medical supervision. This will help consumers avoid a bad trip while also facilitating the therapeutic benefits that these psychedelic substances can provide.

It is also helpful to remember that while an LSD trip is mainly mental, magic mushrooms give rise to an experience that involves a person’s entire body. An LSD trip may last up to ten hours while a mushroom trip usually last about six hours.

All in all, each of these psychedelic substances has its own unique medicinal potential. Consumers should work closely with an experienced psychedelic therapist to determine which of the substances will best serve specific health needs.

With firms such as Cybin Inc. (NEO: CYBN) operating in the sector, the future of the industry seems bright. This company has a management team whose combined efforts have facilitated the closing of pharmaceutical sales worth at least a billion dollars.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.